<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100908">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01998659</url>
  </required_header>
  <id_info>
    <org_study_id>PHS-Px-102-I-01</org_study_id>
    <nct_id>NCT01998659</nct_id>
  </id_info>
  <brief_title>Single Ascending Oral Dose Phase I Study With Px-102</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of Px-102 to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenex Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phenex Pharmaceuticals AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of the FXR agonist Px-102
      in healthy subjects after single oral dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a single-centre, double-blind, randomized, placebo-controlled, parallel group
      phase I study with healthy male subjects receiving ascending single oral oral doses of
      Px-102 to assess the safety and tolerability, pharmacokinetics and pharmacodynamics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of Px-102</measure>
    <time_frame>24h</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event monitoring, laboratory values, cardiovascular monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Px-102 and metabolites</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma, Urine and fecal concentrations (ng/mL) of Px-102 and metabolites measured by LC-MS/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Markers for FXR activation (e.G. FGF19 concentrations (pg/mL) measured by ELISA).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Px-102</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Px-102</intervention_name>
    <description>Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg</description>
    <arm_group_label>Px-102</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral drinking solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject of caucasian origin 18 to 45 years of age

          -  Good state of health (mentally and physically) as determined by medical history,
             physical examination, vital signs, ECG recording and clinical lab results.

          -  BMI in between 20-29 kg/m² with absolute weight in between 70-120 kg.

          -  Serum triglyceride, total cholesterol and liver enzyme levels (alanine
             aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase
             (GGT), alkaline phosphatase (AP)) strictly within the normal ranges at screening and
             on Day -1.

          -  HbA1c ≤ 6.5 %

          -  Subject has been informed both verbally and in writing and has given written consent
             to participation in the study prior to start and any study-related procedure

          -  Negative results for HIV- and Hepatitis-B and -C serology at screening

        Exclusion Criteria:

          -  Female gender

          -  Use of prescription or non-prescription drugs within 7 days (30 if the drug is a
             possible enzyme inducer) prior to administration of study medication. Use of drugs
             known to induce steatosis (e.g. valproate, amiodarone or prednisone) or to affect
             body weight and carbohydrate metabolism

          -  Any acute or chronic illness or clinically relevant finding at screening and at base
             line examination which may jeopardize the subject's participation in the study

          -  History or presence of biliary obstruction or biliary disease, hepatic
             encephalopathy, advanced ascites, portal hypertension, esophageal/gastric variceal
             bleeding, hepatocellular carcinoma, previous liver transplantation or any other
             chronic liver disease

          -  Renal dysfunction, e.g. glomerular filtration rate ≤ 80 ml/min/1,73m2 (as determined
             by the formula of Cockroft-Gault)

          -  Type I or II Diabetes

          -  Any clinically relevant abnormality on screening medical assessment, laboratory
             examination, 12-lead ECG Any clinically relevant finding in the baseline telemetry

          -  Marked baseline prolongation of QT/QTc interval (QTc interval &gt; 440 ms) in the
             12-lead ECG using the Fridericia method for QTc analysis

          -  Heart rate &lt; 50 bpm.

          -  Allergies (except for mild forms of hay fever) or history of hypersensitivity
             reactions

          -  Smoking (regular or irregular) &gt; 5 cigarettes (or equivalent) per day.

          -  Excessive alcohol drinking (more than approximately 20 g alcohol per day), unable to
             refrain from alcohol drinking from 48 h prior to dosing until the last
             pharmacokinetic blood sample has been withdrawn

          -  Positive test for drugs or alcohol at screening or prior to the dosing session

          -  History of alcoholism or drug/chemical/substance abuse within past 2 years

          -  Investigator deems the subject unable or unwilling to comply fully with the study
             protocol

          -  Has received clinical study medication within the last 30 days prior to this study

          -  Donation or loss of 400 ml or more of blood within eight (8) weeks prior to dosing

          -  Allergic to any of the active or inactive ingredients in the study medication

          -  Any other reason which the Investigator considers unsuitable for the subject to
             participate

          -  All subjects (including male subjects with partners of childbearing potential) who do
             not use a highly effective method of birth control (failure rate less than 1 % per
             year when used consistently and correctly), e.g. implants, injectables, combined oral
             contraceptives in combination with a barrier method, some intrauterine contraceptive
             devices or sexual abstinence

          -  Any condition or previous disease leading to puritus or itching of the skin.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Kremoser, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Phenex Pharmaceuticals AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FOCUS Clinical Drug Development GmbH</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
